Autolus Therapeutics Stock

Autolus Therapeutics Dividend 2024

Autolus Therapeutics Dividend

0 USD

Autolus Therapeutics Dividend yield

Ticker

AUTL

ISIN

US05280R1005

WKN

A2JNZJ

How much dividend does Autolus Therapeutics 2024 pay?

According to the latest status from October 2024, Autolus Therapeutics paid a total of 0 USD per share in dividends within the last 12 months. With the current Autolus Therapeutics price of 3.63 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Autolus Therapeutics Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Autolus Therapeutics Dividend Safe?

Autolus Therapeutics has been increasing the dividend for 0 years.

Over the past 9 years, Autolus Therapeutics has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Autolus Therapeutics's Dividend Distributions

Autolus Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Autolus Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Autolus Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Autolus Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Autolus Therapeutics Aktienanalyse

What does Autolus Therapeutics do?

Autolus Therapeutics PLC is a global biopharmaceutical company dedicated to the development of novel therapies for cancer. The company was founded in 2014 by an experienced team of scientists and executives from the biotech industry with the goal of revolutionizing cancer treatment. Autolus Therapeutics' business model is to develop and market novel cancer immunotherapies. The company utilizes innovative technologies such as CAR-T cell therapy and T-cell receptor (TCR) therapy. By targeting the immune system, cancer cells can be recognized and destroyed. Autolus Therapeutics operates a complex network of different sectors and areas to ensure comprehensive development and marketing of its products. This includes research and development, manufacturing and production, as well as clinical testing and approval of therapies. Currently, Autolus Therapeutics focuses on developing therapies for various types of cancer, such as leukemia, lymphoma, and solid tumors. The company has built a broad pipeline of products and therapeutic approaches that are currently in different phases of clinical development. The main focus is on an innovative CAR-T cell therapy, in which the body's own T cells are equipped with a chimeric antigen receptor (CAR) to specifically recognize and combat cancer cells. Autolus Therapeutics' different CAR-T therapies target specific antigens expressed on tumor cells. Another important part of Autolus Therapeutics' pipeline is T-cell receptor (TCR) therapies. T cells are equipped with specific receptors to also target and destroy cancer cells. These therapeutic approaches are currently in clinical development. Autolus Therapeutics collaborates closely with other companies and institutions in the industry to further advance the development and marketing of cancer therapies. This includes strategic partnerships with major pharmaceutical companies such as AstraZeneca and Bluebird Bio. The history of Autolus Therapeutics is characterized by rapid growth and high innovation. Shortly after its founding, the company was able to secure significant funding rounds and international partners. In the following years, the pipeline was further expanded, and the first clinical trials were initiated. Currently, Autolus Therapeutics employs over 250 people at locations in the United Kingdom and the United States. The company has a market capitalization of around $1.5 billion and is considered one of the most promising companies in the biopharmaceutical industry. In summary, Autolus Therapeutics is an innovative and ambitious company dedicated to the research and development of novel cancer therapies. The broad pipeline of products and therapeutic approaches, as well as the close partnerships in the industry, give hope for a promising future of the company. Autolus Therapeutics is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Autolus Therapeutics stock

How much dividend does Autolus Therapeutics pay?

Over the past 12 months, Autolus Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Autolus Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Autolus Therapeutics?

The current dividend yield of Autolus Therapeutics is .

When does Autolus Therapeutics pay dividends?

Autolus Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Autolus Therapeutics?

Autolus Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Autolus Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Autolus Therapeutics located?

Autolus Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Autolus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Autolus Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Autolus Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Autolus Therapeutics in the year 2023?

In the year 2023, Autolus Therapeutics distributed 0 USD as dividends.

In which currency does Autolus Therapeutics pay out the dividend?

The dividends of Autolus Therapeutics are distributed in USD.

Andere Kennzahlen von Autolus Therapeutics

Our stock analysis for Autolus Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Autolus Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.